India is said to have issued show-cause notices over quality concerns to certain Chinese firms which supply active pharmaceutical ingredients (APIs).
India Presses Chinese API Firms Over Quality Concerns
Tougher regulatory scrutiny by India amid its massive reliance on such raw materials from China is anticipated, but the current Indian inspection action is just 'normal regulatory duties,' a Shanghai-based regulatory officer said.
More from Drug Safety
More from Pink Sheet
• By
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
• By
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
• By
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.